The primary hypotheses under test are that alcohol dependent subjects treated with
mifepristone will report decreased craving for alcohol following cue- and stress induced
exposure in the laboratory and report fewer symptoms of protracted abstinence (e.g.,
craving, anxiety, mood and sleep disturbances) under naturalistic conditions, significantly
more than those treated with placebo.
Male or female volunteers, 18-65 years of age
Meets DSM-IV criteria for current alcohol dependence
Subjects will not be seeking treatment because the medication studies are not treatment trials
Subjects must be abstinent a minimum of 3 days (but not more than 7 days) prior to the human lab session
Negative BAC and a CIWA score of < 8 at screening and time of lab session to eliminate acute alcohol or withdrawal effects on dependent measures
Subjects must be able to complete and understand questionnaires and study procedures in English and sign an informed consent
Significant medical disorders that will increase potential risk or interfere with study participation as determined by the Study Physician
Female subjects with childbearing potential who are pregnant, nursing, or refuse to use double barrier (non-hormonal) methods of birth control for the duration of the study and one month thereafter
Meets DSM-IV criteria for a major Axis I disorder including mood or anxiety disorders or substance dependence disorders other than alcohol or nicotine dependence
History of allergy or hypersensitivity to the study drugs or the ingredients
Treatment within the month prior to screening with 1.) an investigational drug or vaccine; 2.) drugs that may influence study outcomes, e.g., disulfiram (Antabuse), naltrexone (ReVia), acamprosate (Campral), anticonvulsants, antidepressants.
In need of or currently taking any psychoactive medications.